canlitinib   Click here for help

GtoPdb Ligand ID: 12865

Synonyms: CX-1003 | CX1003 | Kanitinib
Compound class: Synthetic organic
Comment: The structure for canlitinib was obtained from Proposed INN list 129 (August 2023). Therein it is described as a tyrosine kinase inhibitor with antineoplastic activity. It is the primary compound claimed in patent WO2020216188A1, as an AXL protein kinase and/or vascular endothelial growth factor receptor (VEGFR2, KDR) inhibitor [1]. We predict that canlitinib is Beijing Konruns Pharmaceutical's lead candidate CX-1003. CX-1003 may also inhibit hepatocyte growth factor receptor (HGFR/MET).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 16
Topological polar surface area 135.55
Molecular weight 619.61
XLogP 3.34
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC1=CC2=C(C=C1OCCCCCC(=O)O)N=CC=C2OC3=CC=C(C=C3F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
Isomeric SMILES COC1=CC2=C(C=C1OCCCCCC(O)=O)N=CC=C2OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3F
InChI InChI=1S/C33H31F2N3O7/c1-43-28-18-23-25(19-29(28)44-16-4-2-3-5-30(39)40)36-15-12-26(23)45-27-11-10-22(17-24(27)35)38-32(42)33(13-14-33)31(41)37-21-8-6-20(34)7-9-21/h6-12,15,17-19H,2-5,13-14,16H2,1H3,(H,37,41)(H,38,42)(H,39,40)
InChI Key PCKYITPVOLEZKL-UHFFFAOYSA-N
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
AXL receptor tyrosine kinase Hs Inhibitor Inhibition 9.6 pIC50 - 1
pIC50 9.6 (IC50 2.4x10-10 M) [1]
kinase insert domain receptor Hs Inhibitor Inhibition 9.4 pIC50 - 1
pIC50 9.4 (IC50 3.8x10-10 M) [1]